Table 3.

Incidence of Selected Adverse Events During Each DURATION Clinical Trial

	DURATION-1		DURATION-5		DURATION-2			DURATION-3
	ExQW	ExBID	ExQW	ExBID	ExQW	Sitagliptin	Pioglitazone	ExQW	Glargine
Nausea (%)	26	35	14	35	24	10	5	13	1
Vomiting (%)	11	19	5	9	11	2	3	4	1
Diarrhea (%)	14	13	9	4	18	10	7	9	4
Injection site reactions (%)	30	15	13	10	10	7 (PBO)		13	2
Minor hypoglycemia (%)	5	6	4	3	1	3	1	8	26

The only adverse events not included here that occurred with an incidence ≥10% in any of these DURATION trials were as follows: with exenatide once weekly (ExQW), nasopharyngitis (13% DURATION-3), headache (10% DURATION-3), urinary tract infection (10% DURATION-1), and constipation (10% DURATION-1); with exenatide twice daily (ExBID), upper respiratory tract infection (17% DURATION-1); with pioglitazone, upper respiratory tract infection (10% DURATION-2); and with insulin glargine, nasopharyngitis (17% DURATION-3).

PBO, placebo microsphere injection (combined for sitagliptin and pioglitazone groups).